Physician profile
Benjamin Reese
NPI 1295167989
$8,187.70
in general payments reported to CMS, 2019-2025
32 companies · $1,359 in 2025
The $1,359 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,820 · 2022: $1,714 · 2023: $1,494 · 2024: $1,800 · 2025: $1,359.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,654.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,653.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,778.15 | 2021-2025 | |
| Novo Nordisk INC | $1,238.98 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $797.51 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $767.69 | 2022-2025 | |
| Amgen INC. | $417.24 | 2021-2025 | Repatha, Otezla, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $333.50 | 2021-2025 | Synjardy, Jardiance, Tradjenta |
| Lundbeck LLC | $289.33 | 2021-2025 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $273.90 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $259.02 | 2021-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $219.29 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $207.53 | 2021-2023 | Xarelto |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $193.22 | 2022-2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $190.90 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $168.48 | 2021-2025 | Farxiga, Breztri |
| Biohaven Pharmaceutical Holding Company LTD. | $168.13 | 2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $167.52 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $102.81 | 2024-2025 | Voquezna |
| Acadia Pharmaceuticals INC | $101.99 | 2023-2025 | Daybue |
| Axsome Therapeutics, INC. | $90.54 | 2023-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $78.25 | 2022-2023 | Austedo, Austedo Xr |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $56.31 | 2021-2023 | Xifaxan |
| Glaxosmithkline, LLC. | $47.14 | 2022-2023 | Shingrix, Trelegy Ellipta |
| Sanofi-Aventis U.S. LLC | $41.42 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.42 | 2021-2024 | Trintellix |
| Medtronic, INC. | $27.89 | 2021-2023 | Inpen Smart Insulin Delivery System |
| Merck Sharp & Dohme LLC | $26.22 | 2021-2022 | |
| Bausch Health US, LLC | $22.80 | 2022 | |
| Idorsia Pharmaceuticals US INC | $20.36 | 2022 | |
| Xeris Pharmaceuticals, INC. | $19.06 | 2022 | |
| Paratek Pharmaceuticals, INC. | $19.00 | 2025 | Nuzyra |
| Harmony Biosciences LLC | $17.60 | 2023 | Wakix |
| Mylan Specialty L.P. | $16.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Reese listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.